For the full year, Biogen Idec posted adjusted EPS of $6.53 on revenues of $5.52 billion, compared with EPS of $5.90 on revenues of $5.05 billion in 2011. The consensus estimate called for EPS of $6.58 on revenues of $5.48 billion.
On a GAAP basis, the company reported fourth-quarter EPS of $1.23 and full-year EPS of $5.76.
The company’s CEO said:
We recorded another solid year of revenue growth and profitability, all while advancing our late-stage pipeline and investing in upcoming product launches. We are poised to begin what we expect will be a remarkable period of growth, driven by our promising compounds including TECFIDERA and Peginterferon beta-1a for MS, and both Factor VIII and Factor IX for hemophilia
For 2013, Biogen Idec expects revenues to grow approximately 10% and forecasts adjusted EPS at $7.15 to $7.25, compared with analysts’ consensus estimate of $7.27.
Biogen Idec’s shares are down about 0.1% in premarket trading, at $146.02 in a 52-week range of $114.53 to $157.18. Thomson Reuters had a consensus analyst price target of around $156.70 before today’s report.
The Average American Is Losing Momentum on Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4%* today. Checking accounts are even worse.
But there is good news. To win qualified customers, some accounts are paying nearly 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.